Halda Therapeutics released initial clinical readouts from an ongoing study of its RIPTAC platform in prostate cancer, reporting early signals of activity. The company described a first cut of data that suggest target engagement and tumor responses in some patients, positioning RIPTACs as a novel small-molecule approach that induces targeted protein degradation selectively in tumor cells. Halda said data are preliminary and part of an early-stage program; investigators highlighted the therapeutic class’s ability to recruit intracellular machinery to destroy cancer cells. Investors and partners will watch for expanded cohorts and safety profiles that determine RIPTACs’ feasibility against established prostate cancer agents.